Prevention and management of infection associated with transrectal ultrasound guided prostate biopsy in Ireland
AbstractThe incidence of transrectal ultrasound (TRUS)–guided prostate biopsy associated infection is reportedly increasing, particularly antimicrobial resistant (AMR) infections. To inform development of an inaugural national policy on prevention and management of infection post TRUS biopsy, we conducted a national survey of ten prostate cancer centres that perform approximately 90% of public prostate biopsies in Ireland. An on-line questionnaire regarding prostate biopsy pathways, pre-biopsy AMR risk assessment and antimicrobial prophylaxis regimens, and post-biopsy infection surveillance and management was circulated to all centres. Data from 1st January 2011 to 30th June 2013 were collected retrospectively from July to September 2013. Data were analysed using Microsoft Excel® software. The results of this survey demonstrated marked variation of practices nationally. Three centres reported risk assessing for AMR colonisation pre-biopsy. AMR screening was not conducted routinely in any centre. Antimicrobial prophylaxis regimens, surveillance programmes and empiric therapy guidelines for sepsis also varied between centres. A range of infectious complications were reported, both bloodstream infection (BSI) and non-BSI, however, due to use of non-standardised case definitions, national infection rates could not be generated. At the time of the survey, there were no Irish guidelines and centres followed American and/or European guidelines. Following our survey the National Cancer Control Programme published a “National Policy on the Prevention and Management of Infection post Transrectal Ultrasound-guided Prostate Biopsy” in June 2014 to assist in standardising practice and reducing risk of infectious complications.
Copyright conditions: Copyright on any research article in the International Journal of Infection Control (IJIC) is retained by the author(s). Authors grant IJIC permission to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. IJIC conforms to the Creative Commons Attribution License (http://creativecommons.org) as terms and conditions of publishing research articles. In summary, anyone is free: • to copy, distribute, and display the work; • to make derivative works; • to make commercial use of the work; as long as: • the original author must be given credit; • for any reuse or distribution, it must be made clear to others what the license terms of this work are; • any of these conditions can be waived if the authors gives permission. Statutory fair use and other rights are in no way affected by the above. Authors' certification: In submitting a manuscript to IJIC, authors are requested to certify that: • They are authorized by their co-authors to enter into these arrangements. • They warrant, on behalf of themselves and their co-authors, that: o the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights; o they are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to IJIC are not in breach of any other obligation. If the law requires that the article be published in the public domain, they will notify IJIC at the time of submission; o the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy; o they have taken due care to ensure the integrity of the article.